Building a stable supply system for cell-based pharmaceuticals through a partnership with Promethera Biosciences
First written in FY2020-Q3. 1 of 2 entries say "Restated". Latest entry: FY2021.
0 other companies' latest entry also says "Restated".
- FY2021RestatedAnnual report
「In addition, we are building a logistics platform capable of handling all temperature ranges, including ultra-low temperatures, to deliver regenerative medical products and other products requiring strict temperature control safely and reliably.」
The company continues to pursue a policy of using its logistics infrastructure covering all temperature ranges, including ultra-low temperatures, to ensure a stable supply of regenerative medicine products. - FY2020-Q3First statedAnnual report
「As part of these initiatives, in November 2019 we entered into a business alliance agreement with Promethera Biosciences S.A. (Mont-Saint-Guibert, Belgium). We aim to establish a stable distribution system for Promethera’s innovative development products, from the clinical-trial stage through commercial launch and subsequent supply, by leveraging Medipal’s capabilities and expertise in distributing cell therapies under ultra-low-temperature conditions.」
Starting with the execution of a business alliance agreement in November 2019, the company stated that it would use Medipal's ultra-low-temperature logistics capabilities and expertise to establish a stable distribution system for Promethera products from the clinical-trial stage through post-launch.